187 related articles for article (PubMed ID: 37122357)
1. Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis.
Villeret F; Lebossé F; Radenne S; Samuel D; Roche B; Mabrut JY; Leroy V; Pageaux GP; Anty R; Thevenon S; Ahmed SS; Hamilton A; Heil M; Scholtès C; Levrero M; Testoni B; Zoulim F;
JHEP Rep; 2023 Jun; 5(6):100728. PubMed ID: 37122357
[TBL] [Abstract][Full Text] [Related]
2. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis.
Yasunaka T; Takaki A; Yagi T; Iwasaki Y; Sadamori H; Koike K; Hirohata S; Tatsukawa M; Kawai D; Shiraha H; Miyake Y; Ikeda F; Kobashi H; Matsuda H; Shinoura S; Yoshida R; Satoh D; Utsumi M; Onishi T; Yamamoto K
Hepatol Int; 2011 Dec; 5(4):918-926. PubMed ID: 21484119
[TBL] [Abstract][Full Text] [Related]
3. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.
Lai CL; Wong DK; Wong GT; Seto WK; Fung J; Yuen MF
JHEP Rep; 2020 Jun; 2(3):100112. PubMed ID: 32462119
[TBL] [Abstract][Full Text] [Related]
4. Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
Testoni B; Scholtès C; Plissonnier ML; Paturel A; Berby F; Facchetti F; Villeret F; Degasperi E; Scott B; Hamilton A; Heil M; Lampertico P; Levrero M; Zoulim F
Gut; 2024 Mar; 73(4):659-667. PubMed ID: 37879886
[TBL] [Abstract][Full Text] [Related]
5. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells.
Aggarwal A; Odorizzi PM; Brodbeck J; van Buuren N; Moon C; Chang S; Adona M; Suthram S; Suri V; Trowe T; Turner S; Marcellin P; Buti M; Gaggar A; Fletcher SP; Diehl L; Feierbach B; Balsitis S
JHEP Rep; 2023 Apr; 5(4):100664. PubMed ID: 36908748
[TBL] [Abstract][Full Text] [Related]
6. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
[TBL] [Abstract][Full Text] [Related]
7. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
Darweesh SK; Gad AA; Akroof K; ElLatif ZA
Eur J Gastroenterol Hepatol; 2019 May; 31(5):607-612. PubMed ID: 30724767
[TBL] [Abstract][Full Text] [Related]
8. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
[TBL] [Abstract][Full Text] [Related]
9. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.
Tchervenkov JI; Tector AJ; Barkun JS; Sherker A; Forbes CD; Elias N; Cantarovich M; Cleland P; Metrakos P; Meakins JL
Ann Surg; 1997 Sep; 226(3):356-65; discussion 365-8. PubMed ID: 9339942
[TBL] [Abstract][Full Text] [Related]
10. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
[TBL] [Abstract][Full Text] [Related]
11. Evolving experience of hepatitis B virus prophylaxis in liver transplantation.
Honaker MR; Shokouh-Amiri MH; Vera SR; Alloway RR; Grewal HP; Hardinger KL; Kizilisik AT; Bagous T; Trofe J; Stratta RJ; Egidi MF; Gaber AO
Transpl Infect Dis; 2002 Sep; 4(3):137-43. PubMed ID: 12421458
[TBL] [Abstract][Full Text] [Related]
12. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation.
Hussain M; Soldevila-Pico C; Emre S; Luketic V; Lok AS;
Liver Transpl; 2007 Aug; 13(8):1137-44. PubMed ID: 17663390
[TBL] [Abstract][Full Text] [Related]
13. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study.
Xie SB; Zhu JY; Ying Z; Zeng LJ; Chao M; Lu MQ
Transplantation; 2010 Oct; 90(7):786-90. PubMed ID: 20703179
[TBL] [Abstract][Full Text] [Related]
14. Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?
Campos-Varela I; Castells L; Buti M; Vargas V; Bilbao I; Rodríguez-Frías F; Jardí R; Charco R; Guardia J; Esteban R
Ann Hepatol; 2011; 10(2):180-7. PubMed ID: 21502680
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.
Wong DK; Seto WK; Cheung KS; Chong CK; Huang FY; Fung J; Lai CL; Yuen MF
Liver Int; 2017 Jul; 37(7):995-1001. PubMed ID: 27992681
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: A meta-analysis.
Lai Q; Mennini G; Giovanardi F; Rossi M; Giannini EG
Eur J Clin Invest; 2021 Aug; 51(8):e13575. PubMed ID: 33866547
[TBL] [Abstract][Full Text] [Related]
17. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence.
Lenci I; Tisone G; Di Paolo D; Marcuccilli F; Tariciotti L; Ciotti M; Svicher V; Perno CF; Angelico M
J Hepatol; 2011 Sep; 55(3):587-593. PubMed ID: 21251938
[TBL] [Abstract][Full Text] [Related]
18. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
[TBL] [Abstract][Full Text] [Related]
19. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment.
Wang X; Chi X; Wu R; Xu H; Gao X; Yu L; Liu L; Zhang M; Tan Y; Niu J; Jin Q
Virol J; 2021 Jan; 18(1):4. PubMed ID: 33407619
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
